SC
OLMA icon

Stempoint Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Stempoint Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.75K Buy
+25,000
New +$557K ﹤0.01% 81

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Stempoint Capital's OLMA Position: Q1 2024 in Review

Stempoint Capital sold out of Olema Pharmaceuticals (OLMA) in Q1 2024, closing a stake of 281,287 shares — an estimated $3.95M sold.

Stempoint Capital first reported a position in OLMA in Q4 2023 and held it in 1 quarter. The position peaked at $3.95M in Q4 2023. 126 funds tracked by Wall St. Rank hold OLMA as of Q1 2024.

  • Stempoint Capital reported no remaining Olema Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Stempoint Capital sold 281,287 Olema Pharmaceuticals shares in Q1 2024, an estimated $3.95M.
  • Stempoint Capital first reported a position in Olema Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Stempoint Capital's Olema Pharmaceuticals position peaked at $3.95M in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2024.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.